

Mariana Chavez-MacGregor

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5836172/mariana-chavez-macgregor-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

5,279
citations

34
h-index

71
g-index

117
ext. papers

6,366
ext. citations

5.7
avg, IF

5.47
L-index

#	Paper	IF	Citations
108	Use of Biosimilar Medications in Oncology.. <i>JCO Oncology Practice</i> , 2022 , OP2100771	2.3	1
107	Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients: A Qualitative Analysis.. <i>Patient Preference and Adherence</i> , 2022 , 16, 749-759	2.4	0
106	Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3703-3713	3.1	0
105	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3938-3958	2.2	11
104	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 685-693	2.2	28
103	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021 , 26, e230-e240 ¹	5.7	240 ¹
102	The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa-Maternal Orphans and a Cycle of Disadvantage. <i>JAMA Oncology</i> , 2021 , 7, 197-198	13.4	2
101	Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2021 , 1	3.1	2
100	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020 , 25, 749-757	5.7	8
99	Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. <i>Cancer</i> , 2020 , 126, 3929-3938	6.4	5
98	Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2020 , 25, 937-942	5.7	3
97	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020 , 15, e0229903	3.7	11
96	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR, HER2 Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6417-6428	12.9	5
95	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020 , 27, 359-366	3.1	3
94	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2229-2237	3.1	4
93	Delayed initiation of adjuvant chemotherapy in older women with breast cancer. <i>Cancer Medicine</i> , 2020 , 9, 6961-6971	4.8	6
92	Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?. <i>Plastic and Reconstructive Surgery</i> , 2020 , 146, 945-953	2.7	1

91	Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms. <i>Cancer</i> , 2020 , 126, 3456-3463	6.4	2
90	Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. <i>Drugs and Aging</i> , 2019 , 36, 341-354	4.7	13
89	Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2730-2737	3.1	14
88	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019 , 21, 78	8.3	75
87	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019 , 37, 345-351	4.3	20
86	Ductal Carcinoma In Situ and Margins . <i>Annals of Surgery</i> , 2019 , 269, 150-157	7.8	19
85	Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. <i>Cancer</i> , 2018 , 124, 1760-1769	6.4	7
84	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018 , 267, 946-951	7.8	94
83	Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. <i>JACC: Cardiovascular Imaging</i> , 2018 , 11, 1084-1093	8.4	56
82	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018 , 10, 296-306	0.8	4
81	American Society of Breast Surgeons Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2965-2974	3.1	12
80	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 1300-1309	5.7	28
79	Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. <i>Clinical Neurology and Neurosurgery</i> , 2018 , 173, 61-64	2	6
78	Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. <i>Cancer</i> , 2018 , 124, 899-906	6.4	18
77	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 203-209	13.4	110
76	Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. <i>Cancer</i> , 2018 , 124, 679-687	6.4	23
75	ASCO Resource-Stratified Guidelines: Methods and Opportunities. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	6
74	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2433-2443	2.2	95

73	Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. <i>Cancer</i> , 2018 , 124, 4685-4691	6.4	2
72	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , 2017 , 116, 509-514	8.7	14
71	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017 , 123, 2422-2431	6.4	18
70	Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgery</i> , 2017 , 265, 574-580	7.8	17
69	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. <i>JAMA Oncology</i> , 2017 , 3, 509-515	13.4	97
68	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	23
67	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017 , 123, 3367-3376	6.4	12
66	Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage: An Analysis of Use of Radiation Therapy After Breast-Conserving Surgery. <i>JAMA Oncology</i> , 2017 , 3, 1425-1426	13.4	2
65	Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. <i>Academic Radiology</i> , 2017 , 24, 191-199	4.3	6
64	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017 , 61, 53-60	14.4	31
63	Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3502-3509	3.1	34
62	Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. <i>Lancet Oncology</i> , 2017 , 18, 1568-1569	21.7	1
61	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. <i>Oncologist</i> , 2017 , 22, 1292-1300	5.7	56
60	Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. <i>Cancer</i> , 2017 , 123, 940-947	6.4	15
59	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. <i>Journal of Cancer</i> , 2017 , 8, 2653-2662	4.5	19
58	Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 367-74	4.4	17
57	Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4040-4046	2.2	133
56	Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3801-3810	3.1	123

55	Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1072-8	2.2	430
54	Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 322-9	13.4	177
53	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. <i>JAMA Oncology</i> , 2016 , 2, 929-36	13.4	73
52	Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. <i>Biomarkers in Medicine</i> , 2016 , 10, 315-28	2.3	4
51	Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. <i>Supportive Care in Cancer</i> , 2016 , 24, 2693-706	3.9	5
50	Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1515-21	3.1	53
49	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016 , 7, 76362-76373	3.3	18
48	Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. <i>Practical Radiation Oncology</i> , 2016 , 6, 287-295	2.8	92
47	The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. <i>Regional Anesthesia and Pain Medicine</i> , 2016 , 41, 696-703	3.4	29
46	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 3557-65	3.9	22
45	Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3501-3509	3.1	41
44	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2177-2184	5.7	9
43	Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 339-350	4.4	6
42	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 637-44	4	1
41	Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. <i>Cancer</i> , 2016 , 122, 3447-3455	6.4	19
40	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 407-16	4.4	50
39	Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2176-83	2.2	70
38	Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. <i>Clinical Breast Cancer</i> , 2015 , 15, 153-60	3	27

37	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 713-21	1.9	26
36	Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 417-23	4.4	16
35	Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 90-5	3.1	27
34	Barriers to the Use of Breast Cancer Risk Reduction Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 927-35	7.3	16
33	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015 , 6, 310-8	4.5	14
32	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2239-45	2.2	78
31	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015 , 6, 2604-14	3.3	27
30	Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. <i>Annals of Surgical Oncology</i> , 2014 , 21, 704-16	3.1	259
29	Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 316-23	4	16
28	Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 735-44	2.2	181
27	Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1507-15	2.2	302
26	Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 553-64	4	253
25	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. <i>Lancet Oncology, The</i> , 2014 , 15, e625-e634	21.7	141
24	Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. <i>Cancer</i> , 2013 , 119, 7-15	6.4	43
23	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. <i>SpringerPlus</i> , 2013 , 2, 409		19
22	Tamoxifen therapy for patients with breast cancer. <i>Lancet, The</i> , 2013 , 381, 2077-8	40	2
21	Breast cancer in 2012: New drugs, new knowledge, new targets. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 75-6	19.4	9
20	Mesothelin expression and survival outcomes in triple receptor negative breast cancer. <i>Clinical Breast Cancer</i> , 2013 , 13, 378-84	3	24

19	Trastuzumab-related cardiotoxicity among older patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4222-8	2.2	162
18	Two birds with one stone: octreotide treatment for acromegaly and breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, e398-400	2.2	5
17	Male breast cancer according to tumor subtype and race: a population-based study. <i>Cancer</i> , 2013 , 119, 1611-7	6.4	71
16	Adjuvant bisphosphonates in breast cancer: has the time come?. <i>Breast Cancer Management</i> , 2013 , 2, 327-337	0.7	
15	Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. <i>Journal of Cancer</i> , 2013 , 4, 549-56	4.5	29
14	Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. <i>Cancer</i> , 2012 , 118, 326-32	6.4	8
13	cMET and phospho-cMET protein levels in breast cancers and survival outcomes. <i>Clinical Cancer Research</i> , 2012 , 18, 2269-77	12.9	86
12	Everolimus in the treatment of hormone receptor-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1835-43	5.9	10
11	Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. <i>Clinical Breast Cancer</i> , 2011 , 11, 325-31	3	56
10	Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. <i>Cancer</i> , 2011 , 117, 3641-9	6.4	16
9	Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2628-34	2.2	102
8	Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2645-52	2.2	339
7	Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2010 , 11, 421-8	21.7	227
6	Breast cancer, neoadjuvant chemotherapy and residual disease. <i>Clinical and Translational Oncology</i> , 2010 , 12, 461-7	3.6	14
5	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. <i>Cancer</i> , 2010 , 116, 4168-77	6.4	32
4	Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 101-12	4.4	25
3	Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 147-52	4.4	29
2	Angiogenesis in the bone marrow of patients with breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 5396-400	6.4	28

- 1 Postmenopausal breast cancer risk and cumulative number of menstrual cycles. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 799-804

4 39